AU7690398A - Carotenoid formulation - Google Patents

Description

WO 98/52561 PCT/US98/10356 CAROTENOID FORMULATION FIELD OF THE INVENTION The invention relates to a formulation of a carotenoid composition or a carotenoid dispersed in an oil derived from the esterification of fatty 5 acids and glycerol. More particularly, the invention relates to a formulation of a carotenoid composition or a carotenoid in a medium chain triglyceride oil. BACKGROUND OF THE INVENTION There has been a recent growth in the interest of both researchers 10 and industry in a group of compounds referred to collectively as carotenoids. These occur naturally in plants and animals over a wide base and are generally colored, contributing most of the yellow to red colors in fruits and vegetables. The red of crustaceans like lobsters and the cream color of dairy cream is also due to carotenoids. 15 Epidemiological studies suggest that the carotenoid lycopene (a significant dietary source of lycopene is tomatoes) may exert anti-cancer effects in humans. However, as of the present, there have been no studies on the ability of dietary lycopene to inhibit the development of tumors in established animal models. 20 Due to their high color strength at low concentrations and the high cost of extraction from natural sources, organic chemists successfully synthesized a few carotenoids of economic importance around the middle of this century. Beta-carotene and canthaxathin as well as a few derivatives became commercial products as food colors, dietary 25 supplements and animal product color precursors, notably from the European companies Hoffman- LaRoche AG and BASF AG.

WO 98/52561 PCT/US98/10356 -2 The carotenoids have a unique chemical structure with a backbone of conjugated carbon to carbon double bonds. There are nine double bonds in the main commercial carotenoids which convey special physical and chemical properties to the molecules. In particular, the carotenoids 5 are very reactive with oxygen and free radicals, hence the carotenoids are classified with the traditional anti-oxidants. The carotenoids are present in human, animal and plant tissues. They also are produced in higher concentrations in some living things in response to stress conditions in the environment, such as higher than normal temperatures 10 and high light intensity. Generally they have very low solubilities in water, so they are situated in living cells in association with membranes and lipid aggregates. In living things they are normally present in relatively low concentrations of approximately 10 to 100 ppm. In the production of higher strength commercial carotenoid 15 products, which are available now from the extraction of natural sources as well as synthetic chemical processes, it is necessary to stabilize the carotenoids from oxidation by oxygen in the atmosphere. There is also degradation of the carotenoid molecules by enzymic or microbiological action, but this normally occurs in lower concentrations (for example, 20 less than 0.1%) and in aqueous environments. Naturally the rate of oxidation varies to a large degree with the chemical structure of the carotenoids. Some are extremely reactive and will spontaneously ignite in air in the finely dispersed high concentration crystalline form. Lycopene is one of the most readily oxidized of the common carotenoids 25 and the stabilization of this material or compositions containing this material is of strategic importance in the production of commercial products. The inability to prevent certain of the carotenoids from oxidizing has rendered their commercialization difficult.

WO 98/52561 PCT/US98/10356 -3 Traditionally, stabilization of carotenoids has proven very difficult. One means of helping to prevent oxidation has been to keep the pure crystalline carotenoid materials under an inert gas atmosphere, however, this is only practical on a laboratory scale and not for commercial use. It 5 is also known to suspend carotenoid compositions in triglyceride oils (e.g., soya bean oil) in order to assist in the prevention of oxidation. While the use of standard soya bean oil extracted using solvents and soya beans (which oil has a carbon chain length of mainly between C16 to C 18 ) has proven very effective for some carotenoids such as 13 10 carotene, it has not prevented commercially significant degradation of other carotenoids such as lycopene. SUMMARY OF THE INVENTION The present invention therefore aims to provide a further means to resist the oxidation of carotenoids. Surprisingly, it has been found that 15 the suspension or dispersion of carotenoid compositions or a carotenoid in oils that are derived from the esterification of fatty acids and glycerol (rather than using oils extracted from sources by the use of solvents) decreases the oxidation of carotenoids. Additionally, it has been found that the suspension or dispersion of carotenoid compositions or 20 carotenoid in oils with a chain length of between C 6 to C12 (hereinafter referred to as "medium chain triglyceride oils") has resulted in a significant decrease in the oxidation of carotenoids. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates the stability of the two compositions described 25 in Example 1 (average for each of the vials tested).

WO 98/52561 PCT/US98/10356 -4 Figure 2 depicts the time line for the ten-week study described in Example 2 to determine the maximal tolerated dose (MTD) for lycopene in both male (colon model) and female (breast model) rats. Figure 3 shows HPLC data for echinenone and lycopene. 5 Figure 4 shows HPLC data for all five standard carotenoids, i.e., zeaxanthin, canthoxanthine, echinenone, lycopene, and 1-carotene. Figure 5 is a standard curve for lycopene generated using crystalline lycopene and echinenone. Figure 6 shows the results of HPLC analysis of the Lycopene 10 Suspension. Figure 7 shows the chemical structures of carotenoids present in the Lycopene Suspension. Figures 8-11 illustrate the effects of lycopene on animal weight gain. 15 Figure 12 shows the results of HPLC-MS analysis of saponified organic extracts from livers which indicates the presence of significant amounts of lycopene, phytofluene and phytoene and their geometrical isomers.

WO 98/52561 PCT/US98/10356 -5 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION According to one form of the invention there is provided a formulation including a suspension/dispersion of a carotenoid 5 composition or carotenoid in an oil wherein the oil is derived from the esterification of fatty acids and glycerol. The use of an oil that has been esterified in this way substantially reduces the possibility of introducing into the formulation impurities which are present in oils extracted from sources such as soya bean using solvents. Preferably, substantially pure 10 fatty acids and glycerol are used in the esterification. The fatty acids are preferably purified by distillation. The oil is preferably a medium chain triglyceride oil. Triglycerides are esters of fatty acids and glycerol. The chief constituents of fats and oils, triglycerides have the general formula

CH

2

(OOCR

1

)CH(OOCR

2

)CH

2

(OOCR

3 ), wherein R 1 , R 2 , and R 3 may be of 15 different chain length. In the context of the present invention, preferred triglycerides will have a chain length of C6 to 012, more preferably C 8 to

C

10 According to another form of the present invention, there is provided a formulation including a suspension/dispersion of a carotenoid 20 composition or carotenoid in a medium chain triglyceride oil. Again preferably, the medium chain triglyceride oil has a chain length of C 8 to C1o. It is preferred that the medium chain triglyceride oil is esterified from fatty acids and glycerol. Again, substantially pure fatty acids and glycerol are used in the esterification, with the fatty acids preferably 25 purified by distillation. In a preferred form of the invention, the carotenoid composition predominantly includes carotenoid. Preferably, the carotenoid is selected from the group including lycopene, beta-carotene, zeta-carotene and phtyofluene or mixtures thereof. Lycopene is the preferred carotenoid.

WO 98/52561 PCT/US98/10356 -6 Preferably, the carotenoid composition and carotenoid are derived from natural sources. In a preferred embodiment of the present invention, the medium chain triglyceride oil is the commercially available Delios V T M , a medium 5 chain triglyceride oil produced by Grunan Lebensmitteltechnologie. Another preferred medium chain triglyceride oil is registered as CAS 73398-61-5, a mixed glycerin triester with caprylic and capric acid. This medium chain triglyceride oil is available from the Stepan Co., Northfield, Illinois, under its trademark Neobee®. Preferably, the acid monomers of 10 the medium chain triglyceride oils are selected from the group including C6 caproic acid, C8 caprylic acid, C10 capric acid and C 12 lauric acid or mixtures thereof. It is preferable to use purified fatty acids and glycerol to form the medium chain triglyceride oils as the use of these materials decreases the possibility of the oil containing any impurities that may 15 also cause oxidation of the carotenoid. In a preferred form, the medium chain triglyceride oils are derived from natural sources. In another preferred form of the present invention, the carotenoid comprises up to 10% by weight of the formulation. Preferably, the carotenoid comprises between 4% and 5% by weight of the formulation. 20 In yet another preferred embodiment of the invention, the oil comprises up to 98% by weight, more preferably between 20% and 80% by weight and most preferably between 30% and 70% of the formulation. Preferably, the composition includes an oil soluble anti-oxidant. The addition of an anti-oxidant further assists in preventing the oxidation 25 of the carotenoid. The anti-oxidants are preferably selected from the group including tocopherols, butylated hydroxy anisole, butylated hydroxytoluene, propyl gallate, ethoxyquin and ascorbyl palmitate plus other natural antioxidant extracts which may be derived from herbs and preferably natural tocopherols, and mixtures thereof. Preferably, the WO 98/52561 PCT/US98/10356 -7 tocopherol is selected from the group including beta, gamma- and delta tocopherols or mixtures thereof. In other preferred forms of the invention, the anti-oxidant comprises up to 15% by weight and preferably between 5% and 10% by weight of the formulation. 5 For oral administration, the composition of the present invention optionally further comprises a pharmaceutically acceptable carrier suitable for oral administration. The oral compositions of the present invention can be made by conventional compounding procedures known in the pharmaceutical art, that is, by mixing the active substances with 10 edible pharmaceutically acceptable non-toxic inert, solid or liquid carriers and/or excipients suitable for systemic administration and conventionally used in oral dosage forms. The pharmaceutical compositions for oral administration may be in the form of tablets, including sustained release forms, lozenges, chewing gum, and capsules. The soft gelatin capsule 15 dosage form is most preferred. These dosage forms may be prepared by those skilled in the art in accordance with known techniques in the art, for example, as described in Remington's Pharmaceutical Sciences, 18th Edition (1990), Mack Publishing Co., Easton, PA. The present invention also provides a method of providing a 20 bioavailable antioxidant comprising orally administering to a host an effective amount of lycopene suspended or dispersed in a medium chain triglyceride. In the context of the present invention, the term "host" will be understood to encompass not only humans but also nonhuman animals, particularly mammals. The method comprises administering to 25 the patient an effective amount of a composition comprising a suspension/dispersion of a carotenoid in an oil, such that the dose of carotenoid is between about 1 and 1000 pg/kg. A preferred dose is from about 10 to 100 pg/kg of carotenoid. In practicing this method, a composition according to the present invention may be administered in WO 98/52561 PCT/US98/10356 -8 a single daily dose or in multiple doses per day. The treatment regime may require administration over extended periods of time. The amount per administered dose or the total amount administered will be determined by the physician and depend on such factors as the nature 5 and severity of the disease, the age and general health of the patient and the tolerance of the patient to the compound. The present invention also provides a method for treating or preventing cancer in a patient in need of such treatment. In the context of the present invention, the term "patient" will be understood to 10 encompass not only humans but also nonhuman animals, particularly mammals. The method comprises administering to the patient an effective amount of a composition comprising a suspension/dispersion of a carotenoid in an oil, such that the dose of carotenoid is between about 1 and 1000 pg/kg. A preferred dose is from about 10 to 100 15 p/g/kg of carotenoid. In practicing this method, a composition according to the present invention may be administered in a single daily dose or in multiple doses per day. The treatment regime may require administration over extended periods of time. The amount per administered dose or the total amount administered will be determined by the physician and 20 depend on such factors as the nature and severity of the disease, the age and general health of the patient and the tolerance of the patient to the compound. This method may be practiced by administration of a composition according to the present invention by itself, or in combination with other 25 active ingredients, including other antioxidants, and/or therapeutic agents in a pharmaceutical composition. Other therapeutic agents suitable for use herein are any compatible drugs that are effective by the same or other mechanisms for the intended purpose, or drugs whose WO 98/52561 PCT/US98/10356 -9 actions are complementary to or synergistic with those of the present formulations or compositions. The compounds or agents utilized in combination therapy may be administered simultaneously, in either separate or combined 5 formulations, or at different times than the compositions according to the present invention, e.g., sequentially, such that a combined effect is achieved. The amounts and regime of administration will be adjusted by the practitioner, by preferably initially lowering their standard doses and then titrating the results obtained. 10 With the foregoing and other objects, advantages and features of the invention that will become hereinafter apparent, the nature of the invention is further explained in the following detailed description of the preferred embodiments of the invention and in the appended claims. EXAMPLES 15 EXAMPLE 1: FORMULATION AND STABILITY TESTING In order to demonstrate the improved anti-oxidant effect of the esterified oil, two comparative experiments were conducted using a carotenoid composition which included lycopene as the carotenoid ("the Lycopene Composition"). One experiment involved suspending/ 20 dispersing the Lycopene Composition in soya bean oil extracted using solvents from soya bean and the other involved suspending/dispersing the Lycopene Composition in a medium chain triglyceride oil esterified from fatty acids and glycerol. The results were then compared. Materials 25 The lycopene composition used in the experiments was extracted from tomatoes.

WO 98/52561 PCT/US98/10356 -10 The medium chain triglyceride oil used was manufactured by fractionation of the fatty acids of coconut oil and the esterification of the selected fraction of eight and ten carbon fatty acids with high purity glycerol. Forming the oil in this way may reduce the impurities that 5 appear in oils extracted directly from plant and animal sources. The soya bean oil was a standard oil that had been attracted from soya beans. Two portions of 10 kilograms of the lycopene composition were each dispersed in 15 kilograms of each of the soya bean oil ("Composition 1 ") and the medium chain triglyceride oil ("Composition 10 2") as a diluent or suspending/dispersing oil to form a continuous phase by blending using an efficient mixing procedure. One gram samples of each composition were placed in glass vials for testing. Test Procedures and Results The concentrations of lycopene in each of Composition 1 and 15 Composition 2 were measured using a spectrophotometer to determine the concentration of lycopene at the following times: 0 Month (i.e., shortly after forming the Compositions); 1 Month; 2 Months; and 20 3 Months. (a) Analytical method Each sample was dissolved in chloroform and diluted to a suitable concentration with cyclohexane. Absorbance was measured at specific wavelengths at 20 0 C, and the concentration was calculated from a 25 known extinction coefficient. The following reagents and equipment were used: Spectrophotometer with 10mm glass cells WO 98/52561 PCT/US98/10356 -11 Analytical balance lOOml volumetric flasks 50ml volumetric flasks 2.0ml bulb pipettes 5 Chloroform AR grade Cyclohexane In carrying out the testing, because lycopene is degraded slowly in light, low actinic glass was used. For each sample, the following steps were followed. 0.5 to 1.0 g of 5% lycopene in each of the oils were 10 separately weighed accurately into a 100ml volumetric flask. Approximately 5ml of chloroform was added and the reagents were mixed well to dissolve the samples. Each sample was viewed against light to ensure that it was completely dissolved. 15 To ensure that each sample was completely dissolved, it was allowed to stand for 5 minutes and 5ml additional chloroform was added and warmed under hot tap water (as necessary). The solution was diluted to volume with cyclohexane and mixed well. This was solution A. 2ml of solution A was pipetted into a 50ml 20 volumetric flask and diluted to volume with cyclohexane and mixed well. This was solution B. 2ml of solution B was pipetted into a 50ml volumetric flask and diluted to volume with cyclohexane and mixed well; this was solution C. A spectrophotometer (which had a 2nm slit width) was zeroed 25 using cyclohexane in both cells and the absorbance of solution C was measured at 472nm against a cyclohexane blank. This analysis was conducted in duplicate. In calculating the results, the following standards were used: A= Absorbance of solution C at 472nm WO 98/52561 PCT/US98/10356 -12 m= Weight of sample E= Extinction coefficient E % at 472 nm= 3450 1 cm C= Concentration of lycopene (%) C A x Dilution Exm 5 In the interval between the testing periods both compositions were stored at 250 Celsius. It was found during, testing that lycopene tended to form large crystals, in some cases 2 to 3 mm in size, over a period of months in storage. As the formation of large crystals can substantially influence 10 the assay result, due to sampling error, the one gram samples of the material in glass vials were used which had been prepared immediately after production and stored for stability tests at 250 Celsius. At monthly intervals, vials were removed for assay and the complete contents assayed to overcome the sampling problem due to 15 crystallization. (b) Results The results of the stability of the two Compositions were averaged for each of the vials tested, as shown in Fig. 1 and Table 1: TABLE 1 20 COMPOSITION 1: LYCOPENE IN SOYA Stored at 25 degrees Celsius BEAN OIL TIME FROM PRODUCTION 0 month 1 month 2 months 3 months LYCOPENE CONTENT % wlw 5.0 4.3 3.5 2.9 COMPOSITION 2: LYCOPENE IN Stored at 25 degrees Celsius 25 MEDIUM CHAIN TRIGLYCERIDE OIL TIME FROM PRODUCTION 0 month 1 month 2 months 3 months LYCOPENE CONTENT% wlw 4.3 3.9 4.4 4.3 WO 98/52561 PCT/US98/10356 -13 Discussion of Results The results of the above experiments show that over a three month period, the lycopene concentration in the medium chain triglyceride oil (Composition 2) was relatively constant and in fact the 5 average percentage concentration after three months was the same as the concentration taken immediately after Composition 2 was prepared. The results of the concentration of lycopene in the soya bean oil (Composition 1) shows a steady decline in the % weight of the lycopene over a three month period. 10 The results demonstrate that the oil derived from the esterification of fatty acids and glycerol (in this case a medium chain triglyceride oil) had a stabilizing effect on the oxidation of lycopene. EXAMPLE 2: PRECLINICAL TOXICITY AND STABILITY OF LYCOPENE The purpose of these experiments was to determine the 15 biologically acceptable dose range, uptake and tissue disposition of dietary lycopene. Specific Aims To determine the maximum tolerated dose of lycopene administered in the AIN-76A diet, in male and female Fischer 344 rats 20 and to assess the uptake and disposition of dietary lycopene in blood, feces and various organs such as mammary gland, prostate, colon and lung. Methods Inbred Fischer F344 males (n = 70) and females (n = 70) were 25 obtained from Taconic Farms, Germantown, NY. At about 35 days of WO 98/52561 PCT/US98/10356 -14 age, all animals were transferred to the experimental room from quarantine. The animals were then allocated into experimental groups using formal randomization methods to ensure that each group contained animals of the same mean weight. 5 A ten-week pilot study was conducted as described in Table 2 & Figure 2 to determine the maximal tolerated dose (MTD) for lycopene in both male (colon model) and female (breast model) rats. The choice of dose ranges was based on published values for 0-carotene. A mixed carotenoid composition containing 5.7% carotenoids, including 3.7% 10 pure lycopene was suspended in medium chain triglycerides (this composition will be referred to below as the "Lycopene Suspension"). The Lycopene Suspension was incorporated into the AIN-76A diet. TABLE 2: MTD STUDY No Animals Lycopene quantity 15 Group Males Females (mM/kg diet) Estimated Estimated (% diet) (mglkg diet) (ppm) 1 10 10 2.5 1280 .128 2 10 10 1.0 512 .0512 3 10 10 0.5 256 .0256 4 10 10 0.25 128 .0128 20 5 10 10 0.10 51 .0051 6 20 20 0 0 0 Total N 70 70 a Based on Lycopene MW = 536. The diets were formulated under reduced light and stored at -4oC in air 25 tight containers in 4 kg lots. The components of the AIN-76A diet are listed in Table 3.

WO 98/52561 PCT/US98/10356 -15 TABLE 3: STANDARD AIN-76A DIET INGREDIENT QUANTITY (g/100g) Casein 20 Corn starch 52 5 Dextrose 13 Corn oil 5 DL-Methionine 0.3 Choline Bitartrate 0.2 Alphacel 5 10 AIN-76 Vitamin mix 1.0 AIN-76 Mineral mix 3.5 Total 100 Energy Value (kCal/g) 3.89 Differences in the lipid content of the various treatment groups were 15 controlled by supplementing their diets with appropriate amounts of Neobee® medium chain triglyceride (Stepan Co., Maywood, NJ) such that all animals, including controls, received the same amount of dietary fat. Prior to termination, 3 animals from each group were placed in 20 metabolic cages and 24-hour urine and fecal collections made for subsequent lycopene assay. Blood was collected by heart puncture under anesthesia for lycopene assay and all animals were sacrificed by

CO

2 anesthesia. Blood and feces were stored at -20 0 C. At necropsy, all major organ systems were grossly inspected. Any unusual appearing 25 tissues were placed in formalin and saved for later histological examination. Animal weights were recorded once per week and animal appearance (coat texture) and food avoidance behavior assessed. By concentration, WO 98/52561 PCT/US98/10356 -16 TABLE 4: HPLC METHOD FOR LYCOPENE ASSAY Pump Waters Model 510 Detector Shimadzu, SPD-10A UV-Vis Detector Integrator Waters 745 Data Model 5 Controller Waters Automated Gradient Controller Column Rainin Microsorb 5 pm C18, 25 cm x 4.6mm Wavelength 470 nm Rate 0.7 ml/min AUFS 0.032 10 Chart Speed 0.25 cm/min Volume of Injection 20-50 kl Solvent A 90% Acetonitrile 10% Methanol Solvent B 45% Hexane 15 45% Methylene Chloride 10% Methanol for every 500 ml solvent B, add 0.5 ml Diisopropylethylamine Program 20 Time Solvent A Solvent B 0 95 5 0 95 5 10 95 5 40 55 45 45 95 5 25 65 95 5 Injection Solvent Mixture 40% Acetonitrile 20% Methanol 20% Hexane 30 20% Methylene Chloride WO 98/52561 PCT/US98/10356 -17 the maximal tolerated dose is that dose which results in > 10% mean body weight loss. Quantitative Determination of Lycopene by HPLC The HPLC equipment, solvent systems, and solvent program are 5 outlined in Table 4. Crystalline carotenoids were used as standards including: a-carotene, -carotene, lycopene, zeaxanthin, cryptoxanthin and echinenone (Hoffmann-LaRoche). Echinenone, which is a ketone derivative of P-carotene, was used as an internal standard. Stock solutions of standards were prepared at a concentration of 30 pg/ml in 10 injection solvent (Table 4). (1) Lycopene (RO 01-9251-00) (2) Zeaxanthin (RO 01-9371-000) (3) Cryptoxanthine (RO 04-0763-000) (4) 9-Carotene (RO 01-8300-000) 15 (5) Echinenone (RO 04-2847-000) The variability and reliability of the system was tested by comparing multiple samples from a standard solution of lycopene and echinenone over a period of 5 days (Table 5). The retention times for lycopene varied from a low of 32.58 to a high of 35.95 minutes; that of 20 echinenone varied from a low of 28.54 to a high of 30.64 minutes. The lycopene/echinenone ratio varied from a low of 1.12 to a high of 1.20. A similar low level of within-sample variation was found when integrated areas under curves were compared (Table 5). Using crystalline lycopene and echinenone, a standard curve was 25 generated for lycopene (Fig. 5). Experimental values were read from the standard curve and expressed in terms of either ng/ml or ng/pg/gram tissue wet weight.

WO 98/52561 PCT/US98/10356 -18 TABLE 5: CAROTENOID HPLC STUDY: VARIABILITY AND RELIABILITY Run RT Area Lycopene Echinenone Ratio(LIE) Lycopene Echinenone Ratio (LIE) Day 1 1 33.17 29.15 1.14 586,132 720,121 0.81 5 2 32.91 28.89 1.14 567,339 755,926 0.75 3 33.49 29.86 1.12 527,365 737,088 0.72 4 34.48 30.47 1.13 532,491 765,646 0.70 5 34.47 30.45 1.13 527,024 772,265 0.68 6 34.64 30.64 1.13 496,268 768,335 0.65 10 Day3 7 34.05 28.30 1.20 511,111 781,883 0.65 8 33.04 29.03 1.14 551,826 736,851 0.75 Day 5 9 32.99 28.78 1.15 624,986 803,354 0.78 15 10 32.58 28.32 1.15 573,498 793,606 0.72 11 32.81 28.54 1.15 562,057 823,087 0.68 12 35.95 30.11 1.19 612,266 859,039 0.71 13 34.50 29.86 1.16 543,684 869,292 0.63 X 33.78 29.42 1.15 555,085 783,576 0.71 20 S 0.99 0.85 0.023 37,924 45,566 0.053 C.V. (%) 2.9 2.9 2.0 6.8 5.8 7.5 RT = Retention time in minutes AREA= Integrated area under curve Diet 25 Extraction of lycopene from diet was as follows: A sample of diet containing lycopene was suspended in the injection solvent (Table 4) and homogenized in a polytron homogenizer. Echinenone was added as an WO 98/52561 PCT/US98/10356 -19 internal standard and the mixture centrifuged at 3000 rpm at 4oC for 15 minutes. The supernatant was decanted and saved and the extraction repeated. The pooled extracts were then dried under N 2 gas at 60oC and the residue dissolved in 0.5 ml injection solvent and then subjected 5 to HPLC analysis. The same method, with minor variations, was used for feces and for lung tissue. The efficiency of lycopene extraction from the diet is shown in Table 6 A&B. At any concentration tested the efficiency ranged from 75% at the highest concentration to 100% for the lowest concentration of lycopene. 10 Serum Extraction of lycopene from serum was conducted by adding 1 ml of serum to 0.1 ml echinenone standard in ethanol and 0.9 ml ethanol. The mixture was then vortexed for 20 seconds, and 2.0 ml hexane added and mixed vigorously for 1 minute. The cloudy mixture was then 15 centrifuged at 3,000 rpm for 15 minutes at 4oC and the clear hexane layer was decanted. The above procedure was repeated 3-5 x. The pooled hexane fraction was then dried under N 2 gas at 600C, and the residue dissolved in 0.5 ml HPLC solvent and analyzed by HPLC. Tissue 20 Breast, liver and prostate tissue contain lipids which interfere with the assay. Consequently, a saponification step was required prior to organic extraction. Tissue was homogenized in 20 ml methanol to which echinenone was added as internal standard. For breast tissue, which comprise of 85% adipocytes, 8.0 ml 50% NaOH and 4.0 ml 25% 25 sodium ascorbate was added and the mixture was homogenized. For prostate and liver tissue, which contain less lipid, 4.0 ml and 50% NaOH. and 2.0 ml sodium ascorbate were added and the mixture was WO 98/52561 PCT/US98/10356 -20 TABLE 6A & 6B: EFFICIENCY OF LYCOPENE EXTRACTION FROM THE AIN-76A DIET 6A Group # Lycopene Concentration Sample Volume Volume Lycopene concentration in diet weight of extract injected following extraction (Wg/g) (g) (ml) (pl) (ug/g) 1 1,280 0.5 100 20 975 (76%) 5 2 512 0.5 100 20 321 (63%) X 403 (79%) 3 256 0.5 50 20 192 (75%) 4 128 0.5 50 50 122 (95%) X 101 (86%) 5 51 1.0 50 50 62 (100%) X 52 (100%) 6B 10 No. Echinenone Lycopene Ratio Concentration Area under curve (L/E) (g/g) standard 2,590,806 2,191,332 0.85 2,754,253 2,505,114 0.91 1 2,891,211 4,493,499 1.55 975 2 2,980,758 1,527,316 0.51 321 X 2,618,266 1,663,187 0.64 403 3 2,804,003 1,705,160 0.61 192 15 4 2,236,710 2,179,322 0.97 122 X 2,636,044 2,087,983 0.80 101 5 2,647,478 2,620,900 0.99 62 X 2,613,385 2,171,047 0.83 52 homogenized. Saponification was carried out in 50 ml tubes saturated with N 2 gas overnight in a temperature controlled shaker bath at 30 0 C. Following saponification, 10 ml hexane was added to each tube and 20 vortexed for 1 minute. The mixture was then centrifuged at 2000 rpm WO 98/52561 PCT/US98/10356 -21 for 10 min at 40C and the hexane layer was decanted and saved. This hexane extraction procedure was repeated 5-7 times. The pooled hexane extract was then dried under N 2 gas at 60oC, dissolved in injection solvent and analyzed by HPLC. Lung and colon tissue were 5 processed in an identical manner with the exception that the saponification step was omitted. I. Analysis of the Lycopene Suspension When the Lycopene Suspension (Henkel Corporation, La Grange, IL) was extracted by organic extraction methods, the major carotenoid was 10 lycopene, but a number of other carotenoids were known to be present in tomatoes, a- and -Carotene, phytofluene and phytoene were also present (Figs. 6 & 7). The quantitative profile of carotenoids in the Lycopene Suspension was carried out using an HPLC system as described above, equipped with a photodiode array detector. The six 15 major components can be seen in Table 7. TABLE 7: QUANTITATIVE CAROTENOID PROFILE OF THE LYCOPENE SUSPENSION /g/gm % (g/100 g) % of total carotenoid 1. Lycopene 37,504 3.7504 66 2. -Carotene 12,443 1.2443 22 3. Phytofluene 3,349 0.3349 6 20 4. Phytoene 2,794 0.2794 5 5. zeta-Carotene 440 0.0440 0.7 6. 2,6 cyclolycopene- 471 0.0440 0.7 1,5-diol Total Carotenoids 57,001 5.7 100 WO 98/52561 PCT/US98/10356 -22 Lycopene is present at 3.7%, however, the sum of all the carotenoids is approximately 5.7%. As a consequence, when expressed in terms of % total carotenoids, lycopene comprises 67% of the total, -carotene 20%; the lycopene precursers, phytoflourene and phytoene, 5% each, 5 and z-carotene and 2,6-cyclolycopene-1,5-diol 0.7%. Recalculating the lycopene concentration in the diet based on a 5.72% (rather than 4%) total carotenoid content (67% of which is lycopene) results in the following concentrations per treatment group: Group 1, 1280; Group 2, 512; Group 3, 256; Group 4, 128; and Group 5, 51 (mgs/kg diet). 10 Hence, rather than a pure lycopene preparation, the Lycopene Suspension contains a 5.9% suspension of lycopene, a- and 1-carotene, phytofluene and phytoene (precursors of lycopene) suspended in medium chain triglyceride. This is actually preferable for chemoprevention studies since the carotenoid profile of the Lycopene Suspension is close 15 to that of commercial tomatoes. (See Khachik, F, Beecher, G.R. International Conference on Food Factors: Chemistry and Cancer Prevention. Distribution of carotenoids in fruits and vegetables as a criterion for the selection of appropriate chemopreventive agents. H. Ohigashi (ed.), Springer-Verlag, Tokyo, 1996 (in press). 20 II. Stability in Feed The stability of the lycopene suspension once incorporated into the diet was assessed in two ways. The first was by placing the diet containing the suspension at 4oC in the dark for a period of 3 weeks (Table 8A,B).

WO 98/52561 PCT/US98/10356 -23 TABLE 8A & 8B: DIETARY LYCOPENE STABILITY STUDY a 8A # days Lycopene concentration Group # Date in refrigerator (/gig) %b 1 5/1 1 748 101 5 2 5/8 8 728 98 3 5/14 14 672 90 4 5/21 21 534 72 a AIN-76A diet b Taking concentration of diet (04/40), 744 4g/g, as 100% 10 8B Ratio Concentration Group # Echinenonea Lycopene (L/E) (/tg/g) Area under curve standard 2,461,649 2,117,904 0.86 1 2,304,361 2,486,290 1.08 748 2 2,422,134 2,545,973 1.05 728 15 3 2,325,379 2,265,087 0.97 672 4 2,334,947 1,787,656 0.77 534 a Internal standard At various time points, a diet sample was taken and lycopene was extracted as follows: Approximately 0.5 to 1.0 g of sample was added 20 to a 15 ml volume of extraction solvent consisting of 40% acetonitrile, 20% hexane, 20% methanol and 20% methylenechloride. The mixture was sonicated for 2 minutes and allowed to stand for 5 minutes. The reddish-orange clear supernatant was then decanted. This process was WO 98/52561 PCT/US98/10356 -24 repeated 4 times, at which time the supernatant was colorless. Solvent was then added to a volume of 25 to 100 ml, the mixture centrifuged, and the supernatant decanted. All supernatants were then mixed. The above solvent serves two purposes; first, it is the most efficient mixture 5 for lycopene, and second, it is the same solvent used for injecting lycopene samples into the HPLC. As seen in Table 8, by 3 weeks lycopene decomposes at 4°C in the dark to about 72% of the amount present on day 1; by two weeks, about 10% decomposition occurs. This suggested that a two week storage period would be best for the 10 feeding study. The second was by exposing the lycopene-containing diet to air and light, as is the case in an actual feeding study. The stability of lycopene in the food cup where it is exposed to light and air is seen in Table 9. TABLE 9: STABILITY OF LYCOPENE INCORPORATED INTO AIN-76A 15 DIET AT AMBIENT TEMPERATURE Date Days in food cup Concentration (/pg/g) 4/30 0 744 5/2 2 702 5/3 3 616 20 5/6 6 547 5/7 7 439 5/9 9 624 5/10 10 576 5/13 13 449 25 5/14 14 419 5/15 15 425 5/17 17 431 5/20 20 385 5/21 21 376 WO 98/52561 PCT/US98/10356 -25 It appears that a small amount is lost over a 48-hour period. By 72 hours, approximately 20% of the total lycopene is lost. After 3 weeks, one-half of the original lycopene is no longer measurable. Based on these results, the food was allowed to remain in the food cups for no 5 longer than 48 hours. An analysis of all the major carotenoids present in the Lycopene Suspension-containing diets after 7 months storage at 20oC (Table 10). Note that all the major carotenoids plus the lycopene metabolite present in the Lycopene Suspension are present in the diets in the same relative 10 proportions. However, the net loss of lycopene over 7 months was 66%, 38%, 40%, 44% and 60%, in treatment groups 1-5, respectively; in contrast, -carotene concentrations declined by only 10% of original values over the same time period. TABLE 10: CAROTENOID CONTENT OF DIETS 15 SUPPLEMENTED WITH THE LYCOPENE SUSPENSIONa gigm (ppm) Diet mM/kg 3- zeta- 2,6 diet Lycopene carotene carotene Phytofluene Phytoene cyclolycopene 1,5-dial 1 2.5 472 284 1 58 70 2 2 1.0 348 138 9 28 23 1.4 3 0.5 168 69 4 14 0.32 0.76 20 4 0.25 92 37 2 8 5 0.46 5 0.10 22 8 0 2 1 0.14 6 0 0 0 0 0 0 0 a Diets stored at -20'C for 7 months III. Preliminary Feeding Study 25 One male rat was fed 2.5 mM lycopene (+ other carotenoids)/kg diet for a period of 3 weeks. At this high dose, no change in body WO 98/52561 PCT/US98/10356 -26 weight or food consumption was seen. The feces exhibited a distinct red aspect, as did parts of the coat. The tail was brown. At necropsy, the liver was a deep red, as was the cecum and small intestine. Little discoloration was seen in the abdominal adipose tissue or in the prostate 5 and seminal vesicle. Analysis of the 24 hour fecal pellets for lycopene (Table 11) indicated that approximately 55% of total dietary lycopene consumed was excreted in the feces. This suggests that the remainder was absorbed in the gut. The possibility that some lycopene decomposed 10 upon storage prior to extraction must also be considered. It was found that freeze-drying the fecal pellets prior to lycopene extraction was the most efficacious method for extracting lycopene. This, no doubt, is due to the presence of water in the fecal pellet and to the geometry of the pellet. Once freeze-dried, the fecal pellet can easily be powdered, 15 permitting easier access of the solvent to the fecal matrix.

WO 98/52561 PCTIUS98/10356 27 ~~ LO 4-2 LO) 00 0 -6 0) (0 C.) 0. 0 0 0 CN4 CL a) LO (D) 0. t 0) 1 ah LL 0 ) 0) c -j J 0-~ F- *0 (D Cu a E0 oOo SE LO 1O co N C.) 0 tm

-J

=CO E o m 0Y) 4 C 0 " x WO 98/52561 PCT/US98/10356 -28 IV. Feeding Study (1) Weight Gain The effects of lycopene on animal weight gain can be seen in Tables 12 & 13, Figs. 8-11. There was no difference in the weight gains of 5 rats fed diets supplemented with different doses of lycopene when assessed by analysis of variance for repeated measures. There was an indication by the end of 10 weeks that control rats were gaining weight to a slightly greater extent than supplemented rats, but this difference did not exceed 10%, the usual cut-off point indicating food avoidance or 10 toxicity. TABLE 12: EFFECT OF DIETARY LYCOPENE ON WEIGHT GAIN IN FEMALE F344 RATS' Group Lycopene mixture (ppm) weight (g x SD) Week 0 Week 8 1 1280 86 ± 5 168 ± 10 2 521 86 ± 5 169 ± 9 15 3 251 86 ± 5 171 ± 13 4 128 86 ± 5 173 ± 8 5 51 86 ± 5 168 ± 13 6 Controls 86 ± 5 172 ± 15 a N= 10/group 20 TABLE 13: EFFECT OF DIETARY LYCOPENE ON WEIGHT GAIN IN MALE F344 RATS' Group Lycopene mixture (ppm) weight (gms x SD) Week 0 Week 8 1 1280 113 ± 6 276 ± 30 2 512 113 ± 6 280 ± 19 3 256 113 ± 6 279 ± 26 25 4 128 113 ± 6 279 ± 12 5 51 113 ± 6 280 ± 22 6 Controls 113 ± 6 285 ± 21 a N= 10/group WO 98/52561 PCT/US98/10356 -29 (2) Tissue and Serum Uptake Liver Lycopene was concentrated to a 100-1000 fold greater extent in the liver compared to serum or other organs. Hepatic lycopene levels ranged 5 between 33-120 pg/gm wet weight at the highest dose of lycopene (1280 ppm) (Table 14). TABLE 14: CAROTENOID CONTENT OF LIVERS OF RATS FED DIETS SUPPLEMENTED WITH THE LYCOPENE SUSPENSION a FEMALE /g/gm (ppm) mMikg zeta- 2,6 cyclolycopene 10 Diet diet Lycopene 13-carotene carotene Phytofluene Phytoene 1,5-diol 1 2.5 120 11 17 106 66 9 2 1.0 64 6 8 48 35 5 3 0.5 66 8 7 50 40 7 4 0.25 49 7 2 46 46 4 15 5 0.10 42 4 4 33 38 6 6 0 0 0 0 0 0 0 MALE 1 2.5 33 3 5 30 23 4 2 1.0 5 1 1 5 4 .39 20 3 0.5 60 5 5 34 21 4 4 0.25 3 1 1 -- -- .28 5 0.10 12 1 1 10 10 .34 6 0 0 0 0 0 0 0 The saponified organic extracts from livers, examined by HPLC-MS, 25 indicated the presence of significant amounts of lycopene, phytofluene and phytoene and their geometrical isomers (Fig. 12). In addition, lower WO 98/52561 PCT/US98/10356 -30 levels of zeta-carotene, all trans-3-carotene, 9-cis-1-carotene and 13 cis 1-carotene were also detected. Two oxidative metabolites of lycopene, which have been previously identified in human serum, namely 2,6 cyclolycopene-1,5-diols I & II and 5 their epoxide precursors, 2,6-cyclolycopene-1,5-epoxide I & 11 which have not been detected in human serum, were also detected in the liver samples Quantitation and identification of the former metabolites suggests that, in addition to the dietary source of 2,6-cyclolycopene-1-5 diol, the liver actively metabolizes lycopene to these metabolites as well. 10 The amount of lycopene in female livers was higher, in general, than males and a non-linear dose-response curve was exhibited in males but not females. These results indicate that carotenoids present in the Lycopene Suspension are absorbed and stored in the liver and that lycopene is metabolized in the rat in a manner similar to that found in 15 humans. Serum Serum lycopene levels ranged from a low of 80 to a high of 370 ng/ml. The lycopene concentration in the serum of supplemented animals varied in a non-linear manner with regard to dose in both males 20 and females (Table 15). Surprisingly, the highest concentrations in females were found in groups 3 (200 ppm) and 4 (100 ppm) rather than group 1 (1000 ppm) as expected. Similarly, among males, the highest concentration was in group 3. In females, the low lycopene (40 ppm) group exhibited the lowest concentration of serum lycopene but in males 25 there was no difference between the highest and lowest lycopene groups.

WO 98/52561 PCT/US98/10356 -31 TABLE 15: LYCOPENE CONTENT OF RAT SERUM (ng/ml) " Group No. 5 ± SD Median Range FEMALE 1 187 ± 043 205 123-232 5 2 169 ± 042 180 109-211 3 245 ± 083 210 174--366 4 313 ± 047 308 262--369 5 145 ± 053 152 081 --207 6 0 0 0 10 MALE 1 168 ± 036 160 134--230 2 227 ± 068 225 148--326 3 278 ± 066 285 174--372 4 231 ± 064 215 153--328 15 5 171 ± 049 177 100--238 6 0 0 0 a N=6 These results suggest that serum lycopene levels are regulated by a homeostatic mechanism involving hepatic storage metabolism and 20 release in a manner similar to vitamin A. The serum levels reported here, in rats, are well within the range reported for humans consuming normal levels of tomatoes, or tomato products, i.e., 0.1-5 pg/ml serum (100 5000 ngs/ml). Mammary Gland 25 Lycopene concentrations in the mammary fat pad of female rats ranged from a low of 139 to a high of 460 ng/g wet weight (Table 16).

WO 98/52561 PCT/US98/10356 -32 In contrast to serum, a generalized dose-response effect was seen in mammary tissue with respect to dietary lycopene intake (Table 4). TABLE 16: LYCOPENE CONTENT OF RAT MAMMARY GLAND (ngig)" Group No. - ± SD Median Range 5 1 309 ± 131 235 232--460 2 200 + 030 197 172--231 3 215 ± 062 220 139--282 4 229 ± 054 217 181--288 5 174 ± 057 143 139--239 10 6 0 0 0 SN=3 Prostate Lycopene concentrations in the prostate gland of male rats ranged from a low of 32 to a high of 147 ng/g wet weight (Table 17). On 15 average, the concentration of lycopene in prostate tissue was an order of magnitude lower than mammary tissue. A dose-related pattern of uptake into the prostate was apparent (Table 17). TABLE 17: LYCOPENE CONTENT OF RAT PROSTATE GLAND (ng/g) a Group No. 5 ± SD Median Range 20 1 97 ± 17 99 79-- 112 2 95 ± 48 83 54--147 3 50 ± 37 35 23--93 4 52 ± 26 52 26--77 5 47 ± 16 47 32--63 25 6 0 a N=3 WO 98/52561 PCT/US98/10356 -33 Lung The lycopene content of the lung in male and female rats ranged from a low of 124 to a high of 424 ng/g wet weight (Tables 18 & 19). In the female rat, there appeared to be a plateau effect among groups 1 5 to 4 followed by a definite decrease in the lowest group (Group 5). In males, a similar result was obtained with the exception of an increase in group 4. TABLE 18: CONCENTRATION OF LYCOPENE IN LUNG OF MALE RAT Group No. Concentration Animal No. Concentration (ngs/g) lycopene in diet individual average 10 1 1280 36-1 193 190 36-2 187 2 512 41-1 170 214 41-2 257 3 256 46-1 325 375 46-2 424 4 128 51-1 239 201 51-2 162 5 51 56-1 167 151 56-2 135 15 6 0 61-1 0 0 61-2 0 WO 98/52561 PCT/US98/10356 -34 TABLE 19: CONCENTRATION OF LYCOPENE IN LUNG OF FEMALE RAT Group No. Concentration Animal No. Concentration (ngsigm) lycopene in diet individual average 1 1280 1-1 184 227 1-2 270 2 512 6-1 280 246 6-2 211 5 3 256 11-1 243 193 11-2 142 4 128 16-1 208 211 16-2 214 5 51 21-1 144 134 21-2 124 6 0 26-1 0 0 26-2 0 Colon 10 It was not possible to obtain accurate values for colon tissue because carotenoids entered into the interstices of the mucosa rendering it impossible to assess intracellular (absorbed) carotenoid and luminal (unabsorbed) carotenoid. In general, the colon values appeared to be similar to those of lungs and breast. 15 Glutathione Assays The rationale for measuring glutathione is that the reduced form of the tripeptide thiol, glutathione (Glu-Cys-Gly), participates directly in several key intracellular reactions, including protection against free radical damage. In contrast to carotenoids, which reside in the lipid 20 phase, glutathione is found in the aqueous phase of the cell and there is evidence that lipid and aqueous phase anti-oxidants may interact with one another in such a manner that high levels of one may "spare" or WO 98/52561 PCT/US98/10356 -35 limit the deletion of the other. Total (reduced and oxidized) glutathione assays of blood, liver and kidney (Tables 20-22) were conducted. TABLE 20: WHOLE BLOOD GLUTATHIONE RESULTS - SUMMARY Glutathione (p/mol/g)* Lycopene (ppm) Female Male 5 0 1.010 ± 0.0627 0.936 ± 0.0888 51 0.832 ± 0.158 + 1.030 ± 0.0387 128 0.890 + 0.202 0.920 + 0.169 256 0.848 + 0.0988 0.910 + 0.106 512 0.930 + 0.123 0.990 + 0.141 10 1280 1.080 + 0.104 0.948 ± 0.294 * Values are mean ± S.D., n=5 + Significantly different from control, p <0.05 TABLE 21: LIVER GLUTATHIONE RESULTS - SUMMARY Glutathione (pmol/g)* Lycopene (ppm) Female Male 15 0 5.45 ± 0.366 6.13 + 0.516 51 6.01 ± 0.309 6.77 + 1.53 128 6.54 ± 1.09 + 5.38 + 0.363 256 4.87 + 1.14 4.59 + 1.37 512 5.88 + 0.492 6.90 _ 1.098 20 1280 7.38 + 0.705 + 7.16 + 1.95 + * Values are mean ± S.D., n=5 + Significantly different from control, p <0.05 WO 98/52561 PCT/US98/10356 -36 TABLE 22: KIDNEY GLUTATHIONE RESULTS - SUMMARY Glutathione (pmol/g)* Lycopene (ppm) Female Male 0 0.774 ± 0.154 0.592 ± 0.234 51 0.900 ± 0.101 0.688 ± 0.316 5 128 0.950 ± 0.0758 0.686 ± 0.170 256 1.030 + 0.414 + 0.624 ± 0.104 512 1.090 ± 0.163 + 0.854 ± 0.055 + 1280 0.089 ± 0.045 + 0.828 ± 0.128 + * Values are mean ± S.D., n=5 10 + Significantly different from control, p <0.05 The determination of glutathione was by HPLC with dual electrochemical detection (see Kleinman, W.A. & Richie, J.P., J. Chromatogr B 672:73 80, 1995). In only 1 case, at the highest lycopene level, was there a significant increase in glutathione levels and this occurred only in the 15 liver. No dose-related changes in glutathione were noted in liver, kidney or whole blood. Liver Vitamin A and Vitamin E Assays The effect of the tomato carotenoid supplement on the absorption and storage of two important fat soluble vitamins, namely, retinol and a 20 tocopherol, was investigated. Using established HPLC methods, a strong linear dose-response relationship was found between the lycopene content of the liver and both retinol and a-tocopherol concentrations in female R-344 rats (Table 23).

WO 98/52561 PCT/US98/10356 -37 TABLE 23: CONCENTRATION OF RETINOL AND a-TOCOPHEROL IN RAT LIVER Lycopene in diet Liver Group No. mM/kg Diet mg/kg Diet retinol (pg/gm) a-tocopherol (pglgm) Female 1 2.5 1280 1302 47 5 2 1.0 512 768 38 3 0.5 256 858 39 4 0.25 128 888 46 5 0.10 51 555 32 6 0 0 120 13 10 Male 7 2.5 1280 388 28 8 1.0 512 119 8 9 0.5 256 584 23 10 0.25 128 15 11 0.10 51 454 14 Control 0 0 16 0 In the case of retinol there was a 10-fold difference between controls and the highest lycopene dose; in the case of a-tocopherol there was a 4-fold difference. The data from males were similar. Since the 20 supplement contained little or no retinol vitamin E, all of the retinol and vitamins found in the liver must have come from the AIN-76A diet. Hence, the presence of the carotenoid supplement altered the hepatic uptake and storage of both vitamin A and vitamin E.

WO 98/52561 PCT/US98/10356 -38 Summary (1) The Lycopene Suspension derived from tomatoes consisted of lycopene as the major constituent (70%) followed by a number of other carotenoids including a- and 13-carotene, zeta-carotene, lutein, 5 phytoene and phytofluene. (2) At the dosage range used, lycopene exerted no deleterious effect on food intake or weight gain in either male or female rats. (3) Lycopene was stable in the diet for 7 days at ambient light and temperature and 21 days in the dark at 4 0 C. 10 (4) Approximately 55% of estimated lycopene consumed per day was excreted in the feces. (5) Lycopene was readily absorbed and stored in the rat liver. Lycopene was also metabolized in the liver and the metabolic pathway appears to be similar to that found in humans. Lycopene levels in serum 15 were not related in a linear manner with dietary intake, indicating a relatively tight homeostatic control of serum lycopene levels. The concentration of lycopene in serum was 2 orders of magnitude less than that seen in liver. Lycopene was detected in ng amounts in lung, prostate, colon and mammary tissue. In general, uptake was dose 20 related with the lowest concentrations usually found in the group fed the lowest between males and females, particularly in liver lycopene concentrations. (6) With the exception of the livers obtained from animals fed the highest lycopene levels, glutathione concentrations in whole blood, 25 liver and kidney were similar to controls in both males and females. (7) Liver concentrations of Vitamin E and Vitamin A were altered by the intake of the tomato carotenoid supplement in a dose related manner. Since neither Vitamin E or A were present in the supplement, the increased levels found in the liver involved selective 30 uptake from the diet.

WO 98/52561 PCT/US98/10356 -39 In conclusion, it is clear that in the F-344 rat the entire carotenoid profile in the Lycopene Suspension incorporated into the AIN-76A semipurified diet, is readily absorbed, enters the circulation, and is deposited in all tissues analyzed. The major part of the dietary lycopene 5 absorbed is stored in the liver where it undergoes metabolism in a manner similar to that found in humans. There is no evidence of lycopene toxicity at the dose range used. While the invention has been described and illustrated herein by references to various specific materials, procedures and examples, it is 10 understood that the invention is not restricted to the particular materials, combinations of materials, and procedures selected for that purpose. Numerous variations of such details can be implied and will be appreciated by those skilled in the art.

Claims (16)

1. A carotenoid composition comprising lycopene suspended or dispersed in a medium-chain triglyceride.

2. A composition according to claim 1, wherein the medium chain 5 triglyceride is derived from the esterification of a medium chain fatty acid and glycerol.

3. A composition according to claim 2, wherein the fatty acid is a C6 to C12 fatty acid.

4. A composition according to claim 3, wherein the fatty acid is a C8 10 to C 10 fatty acid.

5. A composition according to claim 2, wherein the fatty acid is selected from the group consisting of caprylic acid, capric acid, lauric acid, and mixtures thereof.

6. A composition according to claim 1, comprising up to 10% by 15 weight lycopene.

7. A composition according to claim 6, comprising between 4% and 5% by weight lycopene.

8. A composition according to claim 6, comprising up to 98% by weight medium chain triglyceride. 20

9. A composition according to claim 8, comprising between 20% and 80% medium chain triglyceride. WO 98/52561 PCT/US98/10356 -41

10. A composition according to claim 9, comprising between 30% and 70% by weight medium chain triglyceride.

11. A composition according to claim 8, further comprising an oil soluble antioxidant. 5

12. A composition according to claim 11, wherein the oil-soluble anti oxidant is selected from the group consisting of tocopherols, butylated hydroxy anisole, butylated hydroxytoluene, propyl gallate, ethoxyquin and ascorbyl palmitate, natural tocopherols, and mixtures thereof.

13. A composition according to claim 12, wherein the tocopherol is 10 selected from the group consisting of beta, gamma-, and delta tocopherols and mixtures thereof.

14. A composition according to claim 11, wherein the anti-oxidant comprises up to 15% by weight of the composition.

15. A composition according to claim 14, wherein the anti-oxidant 15 comprises between 5% and 10% by weight of the formulation.

1 6. A method of providing a bioavailable antioxidant comprising orally administering to a host an effective amount of lycopene suspended or dispersed in a medium chain triglyceride.